Index -
P/E 591.62
EPS (ttm) 0.12
Insider Own 23.03%
Shs Outstand 113.58M
Perf Week 15.90%
Market Cap 7.86B
Forward P/E 214.64
EPS next Y 0.32
Insider Trans -21.21%
Shs Float 87.45M
Perf Month -0.01%
Income 13.28M
PEG -
EPS next Q 0.03
Inst Own 66.19%
Short Float 13.07%
Perf Quarter 51.00%
Sales 728.70M
P/S 10.78
EPS this Y 13.34%
Inst Trans -
Short Ratio 4.87
Perf Half Y 114.85%
Book/sh 5.03
P/B 13.76
EPS next Y 35.37%
ROA 1.55%
Short Interest 11.43M
Perf Year -
Cash/sh 2.93
P/C 23.64
EPS next 5Y -
ROE 3.39%
52W Range 29.05 - 71.60
Perf YTD 60.91%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI 1.52%
52W High -3.41%
Beta -
Dividend TTM -
Quick Ratio 3.20
Sales past 5Y 20.99%
Gross Margin 18.24%
52W Low 138.07%
ATR (14) 3.42
Dividend Ex-Date -
Current Ratio 3.25
EPS Y/Y TTM 122.51%
Oper. Margin 4.31%
RSI (14) 62.61
Volatility 5.91% 5.38%
Employees 8460
Debt/Eq 0.59
Sales Y/Y TTM 29.17%
Profit Margin 1.82%
Recom 1.81
Target Price 65.49
Option/Short Yes / Yes
LT Debt/Eq 0.53
EPS Q/Q 110.85%
Payout 0.00%
Rel Volume 2.48
Prev Close 62.59
Sales Surprise 1.67%
EPS Surprise 412.82%
Sales Q/Q 36.35%
Earnings Feb 27 BMO
Avg Volume 2.35M
Price 69.16
SMA20 8.99%
SMA50 12.44%
SMA200 50.85%
Trades
Volume 5,822,291
Change 10.50%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-15-24 Initiated
Barclays
Equal Weight
$58
Apr-10-24 Upgrade
Argus
Hold → Buy
$70
Jan-29-24 Initiated
Argus
Hold
Dec-21-23 Upgrade
Wedbush
Neutral → Outperform
$35 → $48
Dec-13-23 Initiated
TD Cowen
Outperform
$46
Nov-17-23 Initiated
Raymond James
Mkt Perform
Oct-11-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$45 → $41
Oct-11-23 Initiated
Wedbush
Neutral
$33
Sep-15-23 Initiated
Loop Capital
Hold
$40
Jul-10-23 Initiated
William Blair
Outperform
Jul-10-23 Initiated
Stifel
Buy
$48
Jul-10-23 Initiated
Robert W. Baird
Outperform
$50
Jul-10-23 Initiated
Piper Sandler
Overweight
$45
Jul-10-23 Initiated
Morgan Stanley
Equal-Weight
$43
Jul-10-23 Initiated
JP Morgan
Overweight
$45
Jul-10-23 Initiated
Jefferies
Buy
$48
Jul-10-23 Initiated
Citigroup
Neutral
$42
Show Previous Ratings
Apr-26-24 09:00PM
05:20PM
(Investor's Business Daily)
03:42PM
07:45AM
Apr-25-24 09:00AM
05:50PM
Loading…
Apr-24-24 05:50PM
05:45AM
Apr-22-24 02:15PM
10:00AM
09:45AM
Apr-19-24 10:03AM
(Investor's Business Daily)
Apr-18-24 05:50PM
10:55AM
Apr-17-24 07:37AM
Apr-13-24 12:40PM
09:30AM
Loading…
Apr-12-24 09:30AM
Apr-11-24 02:23PM
(Investor's Business Daily)
10:18AM
(Investor's Business Daily)
09:40AM
09:00AM
05:10AM
Apr-09-24 05:45AM
Apr-07-24 02:00PM
Apr-05-24 06:46AM
Apr-04-24 04:19PM
(Investor's Business Daily) -5.15%
11:36AM
(Investor's Business Daily)
09:35AM
Apr-03-24 09:15AM
Apr-02-24 11:24AM
07:45AM
09:30AM
Loading…
Mar-30-24 09:30AM
Mar-28-24 07:01PM
Mar-25-24 07:01PM
Mar-24-24 08:30AM
Mar-23-24 08:00AM
Mar-22-24 02:16PM
(Investor's Business Daily)
02:16PM
(Investor's Business Daily)
10:23AM
(Investor's Business Daily)
10:00AM
09:25AM
07:30AM
Mar-21-24 04:30PM
08:00AM
(Investor's Business Daily)
Mar-19-24 07:45AM
Mar-18-24 08:28AM
Mar-15-24 04:06PM
(Investor's Business Daily)
Mar-14-24 04:38PM
(Investor's Business Daily)
Mar-12-24 09:45AM
Mar-09-24 08:00AM
Mar-07-24 04:30PM
07:17AM
Mar-04-24 04:09PM
03:57PM
Mar-03-24 10:41AM
Mar-02-24 01:00PM
Feb-29-24 11:32PM
06:12PM
04:07PM
01:41PM
Feb-28-24 10:04AM
09:35AM
Feb-27-24 05:15PM
04:45PM
(Investor's Business Daily)
04:42PM
03:35PM
01:45PM
11:14AM
10:45AM
(The Wall Street Journal)
06:32AM
Feb-26-24 07:25PM
Feb-09-24 03:55PM
Feb-08-24 07:45AM
Feb-06-24 04:30PM
07:45AM
Feb-05-24 10:36AM
Feb-02-24 04:29PM
(Investor's Business Daily)
09:40AM
Jan-29-24 10:35AM
Jan-19-24 08:12PM
Jan-14-24 08:45AM
Jan-13-24 05:02AM
Jan-12-24 08:30PM
Jan-11-24 04:41PM
04:40PM
Jan-09-24 06:19PM
Jan-04-24 12:25PM
Dec-26-23 05:38PM
Dec-22-23 11:13AM
08:15AM
07:00AM
Dec-21-23 05:03PM
02:08PM
11:04AM
08:00AM
Dec-15-23 05:20PM
07:45AM
05:39AM
Dec-14-23 08:30AM
Dec-13-23 09:35AM
09:30AM
Cava Group, Inc. is a holding company, which engages in the operation of restaurants. It operates through the following segments: CAVA, Zoes Kitchen, and Other. The CAVA segment represents the financial results of all CAVA restaurants. The Zoes Kitchen segment focuses on the financial results of all Zoes Kitchen locations. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Xenohristos Theodoros Director Mar 26 '24 Sale 68.29 47,239 3,225,851 526,521 Mar 28 04:01 PM Artal International S.C.A. Director Mar 21 '24 Sale 66.25 2,000,000 132,500,000 26,507,990 Mar 25 04:15 PM SHAICH RONALD M Former 10% Owner Mar 04 '24 Sale 57.20 1,500,000 85,800,000 4,457,634 Mar 06 04:00 PM Xenohristos Theodoros Director Feb 29 '24 Sale 58.51 4,500 263,295 0 Mar 04 04:01 PM Artal International S.C.A. Director Feb 27 '24 Sale 53.60 3,500,000 187,600,000 28,507,990 Feb 29 04:16 PM Schulman Brett CEO and President Dec 06 '23 Option Exercise 1.28 10,000 12,800 1,002,421 Dec 08 04:01 PM Amouyal Philippe Director Nov 17 '23 Buy 33.18 10,000 331,800 15,000 Nov 21 04:00 PM Xenohristos Theodoros Director Jun 20 '23 Buy 22.00 4,500 99,000 4,500 Jun 22 04:33 PM Tolivar Tricia K. Chief Financial Officer Jun 20 '23 Buy 22.00 2,500 55,000 2,500 Jun 22 04:31 PM Bertram Kenneth Robert CLO & Secretary Jun 20 '23 Buy 22.00 2,295 50,490 1,500 Jun 22 04:32 PM Somers Jennifer Chief Operations Officer Jun 20 '23 Buy 22.00 300 6,600 300 Jun 22 04:31 PM
Index RUT
P/E -
EPS (ttm) -0.79
Insider Own 2.72%
Shs Outstand 244.92M
Perf Week -4.24%
Market Cap 389.06M
Forward P/E -
EPS next Y -0.66
Insider Trans 1.52%
Shs Float 239.55M
Perf Month -27.85%
Income -175.61M
PEG -
EPS next Q -0.20
Inst Own 73.90%
Short Float 8.40%
Perf Quarter -13.19%
Sales 1.21M
P/S 321.54
EPS this Y 10.13%
Inst Trans 18.05%
Short Ratio 4.33
Perf Half Y 39.21%
Book/sh 0.38
P/B 4.16
EPS next Y 7.51%
ROA -82.89%
Short Interest 20.12M
Perf Year -34.44%
Cash/sh 0.69
P/C 2.29
EPS next 5Y -
ROE -167.06%
52W Range 0.92 - 3.79
Perf YTD 3.27%
Dividend Est. -
P/FCF -
EPS past 5Y 6.80%
ROI -88.74%
52W High -58.30%
Beta 1.37
Dividend TTM -
Quick Ratio 5.58
Sales past 5Y 186.21%
Gross Margin 46.97%
52W Low 71.74%
ATR (14) 0.15
Dividend Ex-Date -
Current Ratio 5.60
EPS Y/Y TTM -28.28%
Oper. Margin -14253.11%
RSI (14) 33.82
Volatility 7.50% 7.23%
Employees 285
Debt/Eq 1.14
Sales Y/Y TTM 766.91%
Profit Margin -14573.20%
Recom 2.33
Target Price 6.00
Option/Short Yes / Yes
LT Debt/Eq 1.13
EPS Q/Q -21.91%
Payout -
Rel Volume 0.27
Prev Close 1.54
Sales Surprise -43.88%
EPS Surprise 7.92%
Sales Q/Q 2407.14%
Earnings Mar 11 BMO
Avg Volume 4.65M
Price 1.58
SMA20 -17.18%
SMA50 -30.19%
SMA200 -6.66%
Trades
Volume 1,265,773
Change 2.60%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-07-23 Initiated
Jefferies
Hold
$3
Aug-12-22 Initiated
Piper Sandler
Overweight
$10
Jan-29-21 Upgrade
JP Morgan
Underweight → Neutral
$7
Jan-29-21 Downgrade
Wedbush
Outperform → Neutral
$2 → $8
Dec-08-20 Upgrade
Citigroup
Neutral → Buy
Nov-18-20 Upgrade
Gabelli & Co
Hold → Buy
Dec-11-19 Downgrade
Gabelli & Co
Buy → Hold
Nov-08-19 Downgrade
Citigroup
Buy → Neutral
$3 → $4
Sep-11-19 Upgrade
Gabelli & Co
Hold → Buy
$3
Jul-29-19 Downgrade
Stifel
Buy → Hold
$10 → $4
Mar-25-19 Upgrade
Gabelli & Co
Sell → Hold
Jul-31-18 Reiterated
Stifel
Buy
$24 → $23
Feb-23-18 Downgrade
Needham
Buy → Hold
Feb-14-18 Downgrade
JP Morgan
Neutral → Underweight
$10
Mar-01-17 Reiterated
Wedbush
Outperform
$33 → $38
Mar-01-17 Reiterated
H.C. Wainwright
Buy
$26 → $27
Oct-07-16 Initiated
H.C. Wainwright
Buy
$26
Aug-05-16 Reiterated
Wedbush
Outperform
$30 → $31
Aug-02-16 Initiated
Citigroup
Buy
$21
Mar-02-16 Reiterated
Wedbush
Outperform
$26 → $28
Show Previous Ratings
Apr-18-24 08:00AM
Apr-16-24 12:00PM
Apr-03-24 08:00AM
Mar-25-24 09:20AM
Mar-13-24 12:45PM
08:00AM
Loading…
Mar-12-24 08:00AM
Mar-11-24 08:25AM
07:34AM
(Associated Press Finance)
07:15AM
07:05AM
07:00AM
Feb-29-24 10:00AM
Feb-22-24 12:58PM
Jan-31-24 05:06AM
Jan-23-24 05:21AM
07:00AM
Loading…
Jan-08-24 07:00AM
Dec-26-23 05:06AM
Dec-21-23 04:15PM
Nov-30-23 07:30AM
Nov-22-23 07:30AM
Nov-15-23 01:03AM
Nov-12-23 02:10PM
Nov-10-23 04:01PM
10:53AM
Nov-08-23 09:45PM
(Thomson Reuters StreetEvents) -8.80%
07:19AM
(Associated Press Finance)
07:00AM
Nov-03-23 09:00AM
Nov-02-23 09:00AM
Nov-01-23 09:00AM
04:01PM
Loading…
Oct-31-23 04:01PM
Oct-30-23 04:01PM
Oct-25-23 08:45AM
Oct-17-23 04:01PM
01:35PM
Oct-13-23 11:38AM
Oct-11-23 11:13AM
09:00AM
Oct-10-23 11:25AM
09:44AM
03:33AM
Oct-09-23 04:01PM
08:00AM
Sep-28-23 09:00AM
Sep-26-23 09:00AM
Sep-20-23 12:28PM
Sep-14-23 09:40PM
Sep-07-23 04:30PM
09:00AM
Aug-21-23 09:00AM
Aug-17-23 09:56AM
Aug-08-23 09:00AM
Aug-04-23 09:12AM
Aug-03-23 05:15PM
04:10PM
04:01PM
Jul-28-23 04:01PM
08:00AM
Jun-30-23 06:52AM
Jun-27-23 06:46AM
Jun-23-23 08:45PM
09:24AM
Jun-20-23 08:00AM
Jun-15-23 05:00PM
Jun-06-23 04:01PM
Jun-05-23 04:01PM
Jun-04-23 07:00AM
Jun-02-23 09:21AM
Jun-01-23 11:35AM
08:00AM
May-31-23 04:01PM
May-26-23 04:25PM
04:08PM
04:05PM
May-22-23 07:33AM
May-11-23 06:50AM
May-10-23 04:30PM
May-04-23 10:05AM
May-03-23 11:45AM
(Thomson Reuters StreetEvents) +15.13%
May-02-23 04:00PM
Apr-28-23 04:00PM
Apr-22-23 08:15AM
Apr-21-23 09:00AM
Apr-17-23 04:00PM
Mar-06-23 06:00AM
Mar-04-23 12:00PM
10:00AM
Mar-03-23 07:07AM
(Thomson Reuters StreetEvents) +22.94%
Mar-02-23 04:00PM
Feb-28-23 05:00PM
Feb-20-23 08:00AM
Feb-01-23 07:56AM
Jan-06-23 04:05PM
Dec-29-22 06:52PM
Dec-22-22 09:22AM
Dec-21-22 04:30PM
Nov-28-22 08:00AM
Nov-15-22 10:00AM
Nov-14-22 04:03PM
Nov-12-22 07:28AM
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
COATS LONNEL Chief Executive Officer Nov 16 '23 Buy 1.05 90,000 94,797 914,359 Nov 17 04:55 PM COATS LONNEL Chief Executive Officer Nov 10 '23 Buy 1.01 10,000 10,100 824,359 Nov 13 05:31 PM DEBBANE RAYMOND Director Oct 12 '23 Buy 1.03 148,820 153,805 1,340,847 Oct 12 04:01 PM DEBBANE RAYMOND Director Oct 11 '23 Buy 1.08 342,874 370,784 1,192,027 Oct 12 04:01 PM DEBBANE RAYMOND Director Oct 10 '23 Buy 1.14 508,306 579,367 849,153 Oct 12 04:01 PM WADE JEFFREY L President and CFO Sep 14 '23 Buy 1.38 10,000 13,800 264,341 Sep 14 05:05 PM McDermott Wendy VP, Human Resources Aug 04 '23 Buy 1.84 6,000 11,040 28,478 Aug 07 04:13 PM COATS LONNEL Chief Executive Officer Jun 29 '23 Buy 2.16 10,000 21,600 814,359 Jun 29 04:13 PM COATS LONNEL Chief Executive Officer Jun 26 '23 Buy 2.18 10,000 21,792 804,359 Jun 26 04:04 PM COATS LONNEL Chief Executive Officer Jun 23 '23 Buy 2.50 10,000 24,950 794,359 Jun 26 04:04 PM McDermott Wendy VP, Human Resources Jun 23 '23 Buy 2.43 10,000 24,300 22,478 Jun 27 04:22 PM COATS LONNEL Chief Executive Officer Jun 22 '23 Buy 2.31 40,000 92,400 784,359 Jun 22 04:01 PM WADE JEFFREY L President and CFO Jun 20 '23 Buy 2.33 12,000 28,000 254,341 Jun 20 04:10 PM Artal International S.C.A. Director Jun 05 '23 Buy 2.60 27,775,050 72,215,130 78,634,381 Jun 05 04:46 PM Swain Judith L Director May 21 '23 Option Exercise 0.00 9,302 0 40,332 May 22 04:07 PM NIES ALAN S Director May 21 '23 Option Exercise 0.00 9,302 0 41,046 May 22 04:05 PM DEBBANE RAYMOND Director May 21 '23 Option Exercise 0.00 9,302 0 340,847 May 22 04:03 PM LEFKOWITZ ROBERT J MD Director May 21 '23 Option Exercise 0.00 9,302 0 40,332 May 22 04:04 PM Palantoni Frank Director May 21 '23 Option Exercise 0.00 9,302 0 40,332 May 22 04:06 PM SOBECKI CHRISTOPHER J Director May 21 '23 Option Exercise 0.00 9,302 0 159,023 May 22 04:06 PM Amouyal Philippe Director May 21 '23 Option Exercise 0.00 9,302 0 40,332 May 22 04:01 PM BARKER SAM L Director May 21 '23 Option Exercise 0.00 9,302 0 79,617 May 22 04:02 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite